Glaxo seeks flu drug approval

Article Abstract:

Glaxo Wellcome PLC, along with its subsidiary, Glaxo Wellcome Inc., based in Mississauga, Canada, has filed for fast-track approval in Europe and Canada, to market the first inhaled drug for the treatment and prevention of influenza. The companies have applied for approval for Relenza, which works by blocking nueraminadise, an enzyme found on the surface of the fluvirus, effectively preventing the virus from spreading the infection from cell to cell. European and Canadian regulatory approvals could make Relenza available by mid-1999, and an application to market the drug in Australia has already been filed, with a corresponding filing with the US Food and Drug Administration slated to follow before end-1998.

Comment:

Has filed for approval in Europe and Canada to market Relenza, an inhaled drug for the treatment and prevention of influenza

Europe, Government regulation (cont), Antiviral Respiratory Preps, Glaxo Wellcome PLC, Antiviral agents, Respiratory system agents, Glaxo Wellcome Inc., Article

---

QLT shares rise on drug price tag

Article Abstract:

Vancouver, Canada-based QLT PhotoTherapeutics Inc's higher-than-projected price tag for vision drug Visudyne and plans to launch the product in Sept 1999, prompted the company's stock price to hit a record level. In North America, the company set a price of $1,200 for Visudyne, a new laser- activated drug for treating age-related macular degeneration (AMD), up 20% from the consensus projection of $1,000. In the European Union, the preliminary price for the drug has been set at 1,000 euros ($1,070).

Product information, Ophthalmic Drugs, Ophthalmic agents, QLT PhotoTherapeutics Inc.

---

Similar abstracts:

• Abstracts: Conrail sale finally wins approval. Railroad goliaths propose $6B merger. Lockheed to buy Comsat for $2.7B
• Abstracts: Magna bids for remaining Steyr shares. German companies on a takeover blitz. Magna's Austrian unit in running for Mercedes work
• Abstracts: Shulman fuels Draxis fued. Surging Biovail merely catching up. Analysts see bright future for QLT
• Abstracts: Murdoch's satellite TV venture is up in the air. Disney's kingdom counts on bounty from sports
• Abstracts: Loewen mulls selling firm to boost share value. Loewen takes huge writedowns

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.